Conference presentation

Alliance Pharma PLC
07 March 2008


 
For immediate release                                               7 March 2008


                                   RNS REACH

                              ALLIANCE PHARMA PLC

                      ('Alliance Pharma' or 'the Company')


Presentation at the 20th European Congress of the European Board and College of
                          Obstetrics and Gynaecology



Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is
pleased to announce that Mr Andrew Loughney PhD MRCOG, the Head of Obstetrics at
the Royal Victoria Infirmary, Newcastle upon Tyne, will today present a paper on
Isprelor at the 20th European Congress of the European Board and College of
Obstetrics and Gynaecology (EBCOG) in Lisbon, Portugal.


Isprelor is the Company's brand name for its proprietary vaginal preparation of
misoprostol for the induction of labour, which has completed two Phase III
trials.


Mr Loughney was invited by the EBCOG, which brings together 33 countries, to
present the results of one of the Phase III trials at the EBCOG 2008 Congress.
The presentation is entitled A randomised open-label study of intravaginal
misoprostol in comparison with dinoprostone for cervical ripening and induction
of labour in multiparous women.


In the trial, 268 women were given either Isprelor or dinoprostone, the current
standard treatment. Isprelor showed similar effectiveness to dinoprostone and,
importantly, it was less likely to cause nausea, which is a well known side
effect of dinoprostone. Isprelor also has the advantage of not requiring
refrigerated storage.


The combined results of this Isprelor trial and a related Phase III trial have
been submitted for publication in a leading journal.


Further details of the EBCOG 2008 Congress are available at the EBCOG's website,
www.ebcog.org.



For further information:
Alliance Pharma plc                                   + 44 (0) 1249 466966

John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk

Buchanan Communications                              + 44 (0) 20 7466 5000

Mark Court / Rebecca Skye Dietrich

Numis Securities                                     + 44 (0) 20 7260 1000
David Poutney / Michael Meade


Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 34 branded pharmaceutical products and continues to explore
opportunities to expand the range.


Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in the prevention of heart disease, in
Parkinson's disease, in nutrition, in nasal infections, in the treatment of
dermatological conditions, in childbirth and in the treatment of periodontitis
(a serious gum disease). Alliance Pharma's sales are mainly prescription driven.
Its products are distributed to hospitals directly and to pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.


Alliance Pharma is also developing a novel product for sleep disorders.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.




                      This information is provided by RNS
            The company news service from the London Stock Exchange